Novel extended-release formulation of lovastatin by one-step melt granulation: In vitro and in vivo evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 77, Issue 2, 2011, Pages 306-312

  Ochoa, L ^a   Igartua, M ^a   Hernandez R M ^a   Gascon A R ^a   Solinis, M A ^a   Pedraz, J L ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Beagle dog; Extended release; High shear mixer; Lovastatin; Melt granulation

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 6000; MAGNESIUM STEARATE; MANNITOL; MEVINOLIN; MEVINOLINIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG GRANULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL DOG; EXTENDED RELEASE FORMULATION; FOOD DRUG INTERACTION; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DOGS; DRUG COMPOUNDING; EXCIPIENTS; HOT TEMPERATURE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LOVASTATIN; POLYETHYLENE GLYCOLS; SOLUBILITY;

EID: 79551517794     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.11.024     Document Type: Article

References (48)

1. M.A. Bayomi, S.A. Al-Suwayeh, and A.R.M. El-Helw Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation Drug Dev. Ind. Pharm. 27 6 2001 499 506
2. J. Hamdani, A.J. Moes, and K. Amighi Development and evaluation of prolonged release pellets obtained by the melt pelletization process Int. J. Pharm. 245 1-2 2002 167 177
3. A. Royce, J. Suryawanshi, U. Shah, and K. Vishnupad Alternative granulation technique: melt granulation Drug Dev. Ind. Pharm. 22 1996 917 924
4. B.M. Lue, F.S. Nielsen, T. Magnussen, H.M. Schou, K. Kristensen, L.O. Jacobsen, and A. Mullertz Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound Eur. J. Pharm. Biopharm. 69 2 2008 648 657
5. J. Goole, P. Deleuze, F. Vanderbist, and K. Amighi New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer Eur. J. Pharm. Biopharm. 68 2 2008 310 318
6. S. Shimpi, B. Chauhan, K.R. Mahadik, and A. Paradkar Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation AAPS Pharm. Sci. Technol. 5 3 2004 e43
7. N. Passerini, B. Albertini, M.L. Gonzalez-Rodriguez, C. Cavallari, and L. Rodriguez Preparation and characterisation of ibuprofen-poloxamer 188 granules obtained by melt granulation Eur. J. Pharm. Sci. 15 1 2002 71 78
8. D. Yang, R. Kulkarni, R.J. Behme, and P.N. Kotiyan Effect of the melt granulation technique on the dissolution characteristics of griseofulvin Int. J. Pharm. 329 1-2 2007 72 80
9. N. Passerini, B. Albertini, B. Perissutti, and L. Rodriguez Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel Int. J. Pharm. 318 1-2 2006 92 102
10. J. Goole, F. Vanderbist, and K. Amighi Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms Int. J. Pharm 334 1-2 2007 35 41
11. P. Sharma, P. Chaudhari, H. Bhagat, and N. Varia Preparation and characterization of meloxicam-myrj 52 granules obtained by melt granulation Pharm. Technol. 2007
12. L. Ochoa, M. Igartua, R.M. Hernandez, M.A. Solinis, A.R. Gascon, and J.L. Pedraz In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation Eur. J. Pharm. Biopharm. 75 2 2010 232 237
13. J.A. Tobert New developments in lipid-lowering therapy - the role of inhibitors of hydroxymethylglutaryl-coenzyme-A reductase Circulation 76 3 1987 534 538
14. A.W. Alberts Discovery biochemistry and biology of lovastatin Am. J. Card. 62 15 1988 J10 J15
15. M.H. Moghadasian Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors Life Sci. 65 13 1999 1329 1337
16. J.M. Henwood, and R.C. Heel Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipemia Drugs 36 4 1988 429 454
17. H. Lennernas, and G. Fager Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors - similarities and differences Clin. Pharmacokinet. 32 5 1997 403 425
18. R.H. Bradford, C.L. Shear, A.N. Chremos, C. Dujovne, M. Downton, and F.A. Franklin Expanded clinical-evaluation of lovastatin (excel) study results. 1. Efficacy in modifying plasma-lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia Arch. Int. Med. 151 1 1991 43 49
19. G.A. Mcclelland, R.J. Stubbs, J.A. Fix, S.A. Pogany, and G.M. Zentner Enhancement of 3-hydroxy-3-methylglutaryl coenzyme-A (Hmg-Coa) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form Pharm. Res. 8 7 1991 873 876
20. J.X. Sun, R. Niecestro, G. Phillips, J. Shen, P. Lukacsko, and L. Friedhoff Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans J. Clin. Pharmacol. 42 2 2002 198 204
21. M. Lamson, G. Phillips, J. Shen, P. Lukacsko, L. Friedhoff, and R.M. Niecestro Pharmacokinetics of lovastatin extended-release dosage form (lovastatin XL) in healthy volunteers Biopharm. Drug Dispos. 23 4 2002 143 149
22. M.H. Davidson, P. Lukacsko, J.X. Sun, G. Phillips, E. Walters, A. Sterman, R. Niecestro, and L. Friedhoff A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin Clin. Ther. 24 1 2002 112 125
23. L. Ochoa, M. Igartua, R.M. Hernandez, A.R. Gascon, and J.L. Pedraz Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer J Pharm. Pharm. Sci. 8 2 2005 132 140
24. R.W. Korsmeyer, R. Gurny, E. Doelker, P. Buri, and N.A. Peppas Mechanism of solute release from porous hydrophilic polymers Int. J. Pharm. 15 1983 25 35
25. J. Siepmann, and N.A. Peppas Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC) Adv. Drug Deliv. Rev. 48 2-3 2001 139 157
26. Winnolin 4.1. Pharshigt Corporation, Mountain View. California, 2003.
27. Food and Drug Administration: Guidance for Industry. Bioanalytical Methods Validation for Human Studies. US Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research, Rockville, MD, 1998.
28. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (I.C.H.), Q2/R1 Validation of Analytical Procedures. Text and Methodology, 1995.
29. D.E. Duggan, I.W. Chen, W.F. Bayne, R.A. Halpin, C.A. Duncan, M.S. Schwartz, R.J. Stubbs, and S. Vickers The physiological disposition of lovastatin Drug Metab. Dispos. 17 2 1989 166 173
30. P. Colombo, P. Santi, R. Bettini, C.S. Brazel, and N.A. Peppas Drug release from swelling controlled systems D.L. Wise, Handbook of Pharmaceutical Controlled Release Technology 2000 Marcel Dekker New York 183 210
31. K. Kosmidis, P. Argyrakis, and P. Macheras A reappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function Pharm. Res. 20 7 2003 988 995
32. V. Papadopoulou, K. Kosmidis, M. Vlachou, and P. Macheras On the use of the Weibull function for the discernment of drug release mechanisms Int. J. Pharm. 309 1-2 2006 44 50
33. J. Siepmann, A. Streubel, and N.A. Peppas Understanding and predicting drug delivery from hydrophilic matrix tablets using the "sequential layer" model Pharm. Res. 19 3 2002 306 314
34. Andrx Laboratories. Altoprev TM (Lovastatin) Extended Release Tablets. Andrx Laboratories, 2002.
35. B. Abrahamsson, M. Alpsten, B. Bake, U.E. Jonsson, M. Eriksson-Lepkowska, and A. Larsson Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food J. Control. Release 52 3 1998 301 310
36. B. Abrahamsson, K. Roos, and J. Sjogren Investigation of prandial effects on hydrophilic matrix tablets Drug Dev. Ind. Pharm. 25 6 1999 765 771
37. M. Lamson, R. Niecestro, E. Walters, P. Lukacsko, and L. Friedhoff Effects of food on the absorption of lovastatin following administration from an extended-release dosage form J. Clin. Pharmacol. 42 9 2002 1063
38. M.J. Lamson, P. Lukacsko, R.M. Niecestro, L.T. Friedhoff, and A.B. Sterman Pharmacokinetics and pharmacodynamics of extended-release lovastatin J. Clin. Pharmacol. 42 9 2002 1062
39. W.R. Garnett Interactions with hydroxymethylglutaryl-coenzyme-A reductase inhibitors Am. J. Health Syst. Pharm. 52 15 1995 1639 1645
40. K.A. Lentz Current methods for predicting human food effect AAPS. J. 10 2 2008 282 288
41. N. Parrott, V. Lukacova, G. Fraczkiewicz, and M.B. Bolger Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects AAPS J. 11 1 2009 45 53
42. L. Fu, Z. Dai, S. Hou, and Y. Wan Pharmacokinetic study on lovastatin sustained-release tablet and sustained-release capsule in Beagal dogs J. Huazhong. Univ. Sci. Technol. Med. Sci. 24 2 2004 116 119
43. L.Z. Benet, C.Y. Wu, M.F. Hebert, and V.J. Wacher Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery J. Control. Release 39 1996 139 143
44. N. Montvale Mevacor TM Prescribing Information: Physicians Desk Reference 1999 Medical Economics Company
45. C. Kyrklund, J.T. Backman, K.T. Kivisto, M. Neuvonen, J. Laitila, and P.J. Neuvonen Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin. Pharm. Ther. 69 5 2001 340 345
46. A.B. Sterman, L.T. Friedhoff, R.M. Niecestro, M.J. Lamson, and E.I. Cullen Pharmacokinetic variability of an extended release lovastatin formulation J. Clin. Pharmacol. 42 9 2002 1063
47. R. Menon, D. Tolbert, and E. Cefali The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet Biopharm. Drug Dispos. 28 6 2007 297 306
48. J. Lincoln, M.E. Stewart, and S.H. Preskorn How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone J. Psychiatr. Pract. 16 2 2010 103 114